Drugs / BRS201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06420492 | Sep 2025 → Dec 2026 expected | ulcerative colitis | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT06420375 Comparator | May 2025 → Dec 2026 expected | ulcerative colitis | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05835505 Comparator | Dec 2023 → Jun 2026 overdue | primary sclerosing cholangitis | Brigham and Women's Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BRS201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06420375 ↗ |
| Known as | hydroxocobalamin | “This study is a clinical trial being done to investigate the efficacy of drug BRS201 (hydroxocobalamin) as a treatment in patients with primary sclerosing cholangitis.” NCT05835505 ↗ |
| Route | Oral | “in the form of an oral medication” NCT05835505 ↗ |